|
| Wednesday, February 21, 2024 |
|
|
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 |
| Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions. more info >> |
|
| Tuesday, February 20, 2024 |
|
|
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
| Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc. more info >> |
|
| Friday, February 16, 2024 |
|
|
エーザイ、「メトジェクト(R)皮下注ペン」（一般名：メトトレキサート）が日本においてペン型自動注入器注射剤の承認を取得 |
| more info >> |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate). more info >> |
|
| Thursday, February 1, 2024 |
|
|
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa |
| Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. more info >> |
|
| Friday, January 26, 2024 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan. more info >> |
|
| Thursday, January 18, 2024 |
|
|
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan |
| Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. more info >> |
|
| Wednesday, January 17, 2024 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time |
| Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 16, 2024 |
|
|
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 |
| Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually. more info >> |
|
|
エーザイ、ASCO GI および ASCO GU において複数のがんに対する最新の開発研究に関する演題を発表 |
| more info >> |
|
|
|
|
